

Troglitazone (Rezulin) anti-diabetic medication

3D-TOX

Real Time evaluation of metabolic function during constant drug exposure carried out on HepG2-C3A hepatocytes aggregates. Exposure carried out for 24 hours.







Cholestasis







CDFDA / Hoechst



Results:

 TC_{50} = 204 ± 33 μM Time to Onset = 80 to 177 min

Staining for cholestasis conflict with the rapid change of function observed in *real time*, suggesting primary mechanism of damage may be more direct.

Goodness of fit:

SSE: 0.0005957 R-square: 0.9994

Adjusted R-square: 0.9992


RMSE: 0.01409




Troglitazone (Rezulin) anti-diabetic medication

3D-RISK

Real time metabolic analysis carried out on HepG2/C3A hepatocyte aggregates exposed to 50 μ M troglitazone. Cell viability throughout was greater than 90%





Calculated metabolic fluxes in $nmol/min/10^6$ cells untreated cells (control) and cells exposed to troglitazone for 15 hours. ATP production of troglitazone-exposed cells is within 97% of untreated cells.

Pathway	Control (0h)	Troglitazone (15h)	Comments
Glycolysis	1.49	2.25	51% increase
Respiration	0.31	0.25	20% decrease
Glutaminolysis	0	0.02	Minor contribution
Lipogenesis	0.62	0	Indication for long-term accumulative damage

